Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
5.49
Dollar change
+0.13
Percentage change
2.43
%
Index- P/E- EPS (ttm)-1.49 Insider Own50.42% Shs Outstand23.60M Perf Week8.50%
Market Cap223.50M Forward P/E- EPS next Y-1.39 Insider Trans0.00% Shs Float20.19M Perf Month113.62%
Income-49.11M PEG- EPS next Q-0.39 Inst Own37.10% Short Float0.21% Perf Quarter300.73%
Sales7.20M P/S31.04 EPS this Y28.74% Inst Trans-0.35% Short Ratio0.15 Perf Half Y150.68%
Book/sh2.10 P/B2.62 EPS next Y0.60% ROA-47.16% Short Interest0.04M Perf Year131.65%
Cash/sh2.65 P/C2.07 EPS next 5Y- ROE-59.95% 52W Range1.01 - 5.55 Perf YTD87.37%
Dividend Est.- P/FCF- EPS past 5Y-45.10% ROI-55.45% 52W High-1.08% Beta2.72
Dividend TTM- Quick Ratio4.59 Sales past 5Y0.00% Gross Margin95.88% 52W Low443.56% ATR (14)0.39
Dividend Ex-Date- Current Ratio4.59 EPS Y/Y TTM20.62% Oper. Margin-735.06% RSI (14)83.39 Volatility9.11% 12.29%
Employees27 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin-681.94% Recom1.00 Target Price8.57
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q37.28% Payout- Rel Volume0.85 Prev Close5.36
Sales Surprise36.58% EPS Surprise15.09% Sales Q/Q- EarningsNov 13 AMC Avg Volume294.70K Price5.49
SMA2031.62% SMA5078.10% SMA200143.01% Trades Volume249,362 Change2.43%
Date Action Analyst Rating Change Price Target Change
Feb-21-24Initiated Guggenheim Buy $10
Dec-17-21Initiated Oppenheimer Outperform $15
Dec-10-21Initiated The Benchmark Company Speculative Buy $7
Nov-16-21Downgrade SVB Leerink Outperform → Mkt Perform
Jul-19-21Initiated H.C. Wainwright Buy $30
Apr-26-21Resumed Credit Suisse Outperform $26
Nov-03-20Initiated SVB Leerink Outperform $35
Nov-03-20Initiated RBC Capital Mkts Outperform $28
Nov-03-20Initiated Credit Suisse Outperform $28
Nov-03-20Initiated Cowen Outperform $44
Jan-30-24 04:05PM
Jan-22-24 08:00AM
Jan-05-24 08:00AM
Jan-04-24 08:00AM
Nov-13-23 04:05PM
04:05PM Loading…
Nov-02-23 04:05PM
Oct-18-23 08:00AM
Aug-28-23 04:00PM
Aug-14-23 04:00PM
Jul-24-23 12:00PM
Jun-12-23 04:00PM
May-25-23 08:00AM
May-24-23 04:05PM
May-22-23 09:30AM
May-16-23 06:18AM
08:00AM Loading…
May-15-23 08:00AM
May-04-23 04:05PM
May-02-23 04:05PM
Mar-31-23 12:00PM
Mar-16-23 04:00PM
Feb-28-23 04:05PM
Feb-23-23 10:43AM
Feb-10-23 08:00AM
Feb-09-23 08:00AM
Feb-01-23 04:05PM
Jan-31-23 09:55AM
Jan-09-23 08:05AM
Jan-06-23 05:54PM
06:16AM
Jan-05-23 04:00PM
01:13PM Loading…
Nov-16-22 01:13PM
Nov-10-22 04:01PM
Oct-26-22 04:05PM
Aug-30-22 04:05PM
Aug-10-22 04:05PM
Jun-01-22 04:01PM
May-31-22 08:00AM
May-11-22 04:01PM
May-03-22 04:05PM
Apr-11-22 08:00AM
Mar-14-22 04:05PM
04:01PM
Mar-01-22 04:05PM
Feb-03-22 04:05PM
Jan-24-22 08:00AM
Jan-19-22 09:38PM
Jan-05-22 08:00AM
Dec-31-21 01:50PM
Dec-17-21 07:27AM
07:16AM
Dec-14-21 10:00AM
Nov-18-21 04:05PM
Nov-15-21 04:05PM
04:01PM
Sep-29-21 01:06PM
Sep-07-21 04:05PM
Aug-25-21 09:00AM
Aug-11-21 08:55AM
Aug-10-21 04:05PM
11:59AM
Jul-23-21 10:14AM
Jul-07-21 11:38AM
Jun-24-21 08:07AM
Jun-21-21 08:03AM
May-24-21 08:01AM
May-13-21 04:05PM
May-12-21 04:05PM
Mar-22-21 04:05PM
Mar-17-21 08:00AM
Mar-02-21 08:00AM
Feb-17-21 04:05PM
Jan-12-21 05:10AM
Jan-06-21 08:00AM
Dec-17-20 04:05PM
Nov-18-20 04:05PM
Nov-04-20 04:05PM
Oct-16-20 07:38PM
Oct-14-20 04:05PM
Oct-09-20 03:49PM
01:28PM
11:51AM
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gharib Samir M.President & CFODec 15Option Exercise0.00112,2500204,403Dec 18 08:16 PM
Charlton Ralph William IIIChief Medical OfficerDec 15Option Exercise0.0031,750056,992Dec 18 08:17 PM
Szwarcberg Javier B.Chief Executive OfficerDec 15Option Exercise0.00111,0000145,705Dec 18 08:15 PM